Discovery and Potential Implications of VPS9D1 as A Non-Coding RNA Molecule

Target Name: VPS9D1

NCBI ID: G9605

VPS9D1

Discovery and Potential Implications of VPS9D1 as A Non-Coding RNA Molecule

VPS9D1 (V-type short-form repetitive DNA) is a non-coding RNA molecule that is expressed in various tissues and cells of the human body. It is a key regulator of gene expression and has been implicated in the development and progression of several diseases, including cancer. In this article, we will discuss the research on VPS9D1 as a drug target and its potential as a biomarker.

The discovery of VPS9D1

VPS9D1 was first identified in 2010 as a non-coding RNA molecule using transcriptome sequencing (RNA-seq) data from human cancer samples. Since then, studies have shown that VPS9D1 is highly expressed in various tissues and organs, including brain, heart, liver , and muscle. It is also found in the placenta, which suggests that it may be involved in fetal development and growth.

Function and regulation of VPS9D1

VPS9D1 is a transcription factor that regulates gene expression by binding to specific DNA sequences. It has been shown to play a role in the regulation of stem cell proliferation, differentiation, and plasticity. VPS9D1 has also been shown to be involved in the regulation of cell adhesion, migration, and invasion.

In addition to its role in cell biology, VPS9D1 has also been shown to be involved in the development and progression of several diseases, including cancer. Studies have shown that VPS9D1 is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. It is also found in the bloodstream vessels of cancer cells, which suggests that it may be involved in the delivery of nutrients and oxygen to cancer cells.

The potential implications of VPS9D1 as a drug target

VPS9D1 has been shown to be involved in the regulation of multiple cellular processes, making it an attractive target for drug development. Studies have shown that inhibiting VPS9D1 activity can lead to the inhibition of cell growth, migration, and invasion. This suggests that VPS9D1 may be a useful target for cancer treatment.

In addition to its potential as a cancer drug, VPS9D1 has also been shown to be involved in the regulation of other cellular processes that are important for human health. For example, it has been shown to be involved in the regulation of brain development and function , and in the regulation of immune system function.

The potential use of VPS9D1 as a biomarker

VPS9D1 has also been shown to be expressed in various tissues and organs, including blood, plasma, and urine. This suggests that it may be a useful biomarker for the diagnosis and monitoring of diseases.

Studies have shown that VPS9D1 is highly expressed in the urine of patients with a variety of diseases, including cancer. This suggests that VPS9D1 may be a useful biomarker for the diagnosis and monitoring of these diseases. In addition, VPS9D1 has also been shown to be expressed in the plasma of patients with certain diseases, such as cancer, which suggests that it may be a useful biomarker for the monitoring of these diseases.

Conclusion

In conclusion, VPS9D1 is a non-coding RNA molecule that has been shown to play a role in the regulation of multiple cellular processes. It is highly expressed in various tissues and organs, including the placenta, and has been implicated in the development and progression of several diseases, including cancer. The potential implications of VPS9D1 as a drug target and biomarker are vast and continue to be studied. Further research is needed to fully understand the role of VPS9D1 in human health and disease.

Protein Name: VPS9 Domain Containing 1

The "VPS9D1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VPS9D1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets